Istituto Oncologico della Svizzera Italiana
   
    PER APPUNTAMENTI:
    Ambulatorio di Bellinzona: +41 91 811 91 47            
    Ambulatorio di Locarno: +41 91 811 45 76            
    Ambulatorio di Lugano: +41 91 811 79 00            
    Ambulatorio di Mendrisio: +41 91 811 33 96
 
    Radioterapia: +41 91 811 86 75
 
    Durante la notte e il week-end rivolgersi al Reparto degenti
    URGENZE: +41 (0)91 811 86 12
 
Istituto Oncologico della Svizzera Italiana

iosi@eoc.ch

   
    PER APPUNTAMENTI:
    Ambulatorio di Bellinzona: +41 91 811 91 47            
    Ambulatorio di Locarno: +41 91 811 45 76            
    Ambulatorio di Lugano: +41 91 811 79 00            
    Ambulatorio di Mendrisio: +41 91 811 33 96
 
    Radioterapia: +41 91 811 86 75
 
    Durante la notte e il week-end rivolgersi al Reparto degenti
    URGENZE: +41 (0)91 811 86 12
 
Istituto Oncologico della Svizzera Italiana

Multiple myeloma and plasma cell neoplasms Back

 
Our institute has the competence to establish diagnostics according international standards, both at clinical-oncological and laboratory-instrumental level thanks to the excellent collaboration among different actors:
 
  • Cantonal Institute of Pathology
  • Immunology Laboratory: LC-CIC
  • Cytogenetics Laboratory
  • EOC Nephrology
  • EOC Orthopedics
  • EOC Diagnostic and Interventional Radiology
  • Amyloidose-Netzwerk, Zurich;
  • Prof. dr. med. Giovanni Palladini, Center for the Study and Treatment of Systemic Amyloidosis, Pavia (I); 
  • Prof. dr. med. Dr.med. St. Schönland, Amyloidosezentrum, Uniklinikum Heidelberg (D).
 
For the specific therapy of multiple myeloma, international recommendations are followed and the most modern medications are applied, partly in the context of clinical trials.
The therapeutic approach is often multimodal and may involve the services of interventional radiology, radiation oncology, orthopedics or nephrology, depending on the clinical problem.
The first-line therapy of the patient up to 75 years of age still involves autologous stem cell transplantation, while the therapeutic choices for the elderly patient are more personalized.

As far as rarer plasma cell neoplasms (amyloidosis) are concerned, there is an active and close collaboration with the Amyloidose-Netzwerk at the University Hospital of Zurich and with the international reference centers in Pavia (I) and Heidelberg (D). 

Back